1
Exhibit 10.22
FOURTH AMENDED AND RESTATED VOTING AGREEMENT
AGREEMENT, dated as of December 17, 1998 among Aspect Medical Systems,
Inc., a Delaware corporation (the "Company"); those persons whose names are set
forth under the heading "Preferred Shareholders" on Schedule I hereto (the
"Preferred Shareholders"); those persons whose names are set forth under the
heading "Common Shareholders" on Schedule I hereto (the "Common Shareholders");
and those persons who shall, after the date hereof, join in and become a party
to this Agreement by executing and delivering to the Company an Instrument of
Accession in the form of Schedule II hereto.
WHEREAS, the Common Shareholders, certain of the Preferred Shareholders
and the Company are parties to a certain Third Amended and Restated Voting
Agreement dated February 13, 1998 (the "Old Voting Agreement"), pursuant to
which the Common Shareholders and certain of the Preferred Shareholders agreed
to vote their shares of capital stock of the Company in a certain manner with
respect to the election of the Board of Directors of the Company;
WHEREAS, pursuant to a Series E Convertible Preferred Stock and Warrant
Purchase Agreement dated as of the date hereof between the Company and the
purchasers listed on Schedule I thereto (the "Purchase Agreement"), certain of
the Preferred Shareholders are purchasing (a) Series E Convertible Preferred
Stock, $.01 par value per share (the "Series E Preferred Stock") and (b)
Warrants (the "Warrants") to purchase shares of Common Stock, $.01 par value per
share, of the Company (the "Common Stock"); and
WHEREAS, it is a condition to the obligations of the Preferred
Shareholders purchasing Series E Preferred Stock and Warrants pursuant to the
Purchase Agreement that this Agreement be executed by the parties hereto to
amend and restate the Old Voting Agreement as set forth herein, and the parties
are willing to execute this Agreement and to be bound by the provisions hereof.
NOW, THEREFORE, in consideration of the premises and mutual covenants
contained herein, the parties hereto agree as follows:
1. Amendment to Old Voting Agreement. The Old Voting Agreement is
hereby amended and restated upon the terms and conditions contained in this
Agreement to read in its entirety as provided herein.
2. Definitions. As used in this Agreement, the term "Shares" shall mean
any voting securities of the Company currently owned (either beneficially or of
record) or subsequently acquired by any party to this Agreement, including any
securities which such party does not own (either beneficially or of record) but
as to
-1-
2
which such party exercises voting control, and including, without limitation,
shares of Common Stock acquired upon conversion of shares of convertible
preferred stock or upon exercise of options or warrants to purchase Common
Stock.
3. Term. The term of this Agreement shall commence on the date hereof
and shall terminate upon the earlier of (i) the closing of a firm commitment
underwritten public offering of shares of Common Stock which (a) results in
aggregate gross proceeds of at least $20,000,000, and (b) is at a price per
share of at least $14.00, which number shall be appropriately adjusted for stock
splits, stock dividends, combinations, reorganizations, recapitalizations and
other similar events involving a change in the capital structure of the Company,
or (ii) the tenth anniversary of the date of this Agreement.
4. Board of Directors.
(a) Each party covenants and agrees that it shall vote all of
its Shares so that the Company's Board of Directors shall consist of no more
than nine members, unless the number of members of the Board of Directors of the
Company is expanded pursuant to paragraph (e) below.
(b) Each party covenants and agrees that at any and all
meetings (including any written action in lieu of a meeting of shareholders of
the Company at which directors are to be elected) each party shall at all such
times vote all of its Shares, to the extent permitted pursuant to the Company's
Restated Certificate of Incorporation (as it may be further amended or restated
from time to time), to cause and maintain the election to the Board of Directors
of the Company of:
(i) one nominee selected by ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
("▇▇▇▇▇▇▇"), subject to paragraph (c) below;
(ii) two nominees designated by a majority of the
Series B-1 Convertible Preferred Stock, $.01 par value per share (the "Series
B-1 Preferred Stock") and the Series B-2 Convertible Preferred Stock, $.01 par
value per share (the "Series B-2 Preferred Stock"), voting together as a single
series;
(iii) one nominee designated by a majority of the
Series A-1 Convertible Preferred Stock, $.01 par value per share (the "Series
A-1 Preferred Stock"), and the Series A-2 Preferred Stock, $.01 par value per
share (the "Series A-2 Preferred Stock"), voting together as a single series,
and acceptable to both Aeneas Venture Corporation (for so long as it holds
shares of Series A-1 Preferred Stock or Series A-2 Preferred Stock) and New
Enterprise Associates IV, Limited Partnership (for so long as it holds shares of
Series A-1 Preferred Stock or Series A-2 Preferred Stock);
-2-
3
(iv) one nominee selected by Polaris Venture
Partners, L.P. ("Polaris") (for so long as it holds shares of Series C
Convertible Preferred Stock, $.01 par value per share (the "Series C Preferred
Stock"), or Series C-2 Convertible Preferred Stock, $.01 par value per share
(the "Series C-2 Preferred Stock"), or, in the event that Polaris no longer
holds shares of Series C Preferred Stock or Series C-2 Preferred Stock, by the
holders of a majority of shares of Series C Preferred Stock and Series C-2
Preferred Stock);
(v) one nominee selected by the holders of a
majority of the shares of Series D Convertible Preferred Stock, $.01 par value
per share (the "Series D Preferred Stock") and Series D-2 Convertible Preferred
Stock, $.01 par value per share (the "Series D-2 Preferred Stock"), voting
together as a single series;
(vi) one nominee selected by a majority of the
directors designated pursuant to clauses (ii) through (v) of this Section 4(b);
and
(vii) two additional nominees who shall be agreed
upon by the management of the Company and a majority of the directors designated
pursuant to clauses (ii) through (v) of this paragraph (b); provided, however,
that one of the nominees selected pursuant to this clause (vii) shall not be any
person affiliated with the Company's management, the holders of Series B-1
Preferred Stock, Series A-1 Preferred Stock, Series C Preferred Stock, Series D
Preferred Stock, Series A-2 Preferred Stock, Series B-2 Preferred Stock, Series
C-2 Preferred Stock or Series D-2 Preferred Stock (a "Non-Affiliated Director");
provided further that each party agrees to vote their Shares to remove such
Non-Affiliated Director if such removal is recommended by a majority of the
directors designated pursuant to clauses (ii) through (v) of this paragraph (b).
(c) Notwithstanding paragraph (b) above, ▇▇▇▇▇▇▇ shall be
entitled to designate one nominee to the Board of Directors of the Company only
if, at the time of any such nomination, he is then employed by the Company or
serving as a consultant to the Company at its request. Commencing with the date
▇▇▇▇▇▇▇'▇ relationship with the Company as an employee or consultant terminates
and thereafter, the nominee to which ▇▇▇▇▇▇▇ would otherwise have been entitled
to designate pursuant to clause (i) of paragraph (b) above, shall be such person
who is designated by the Chief Executive Officer of the Company and approved by
a majority of nominees or directors who were nominees designated pursuant to
clauses (ii) through (v) of paragraph (b) above.
(d) The parties agree that (i) the initial nominee designated
by ▇▇▇▇▇▇▇ is ▇▇▇▇▇▇▇, (ii) the initial nominees designated by the majority of
the Series B-1 Preferred Stock are ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ and ▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.,
(iii) the initial nominee designated by the majority of the Series A-1 Preferred
Stock is ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ Eagle, (iv) the initial nominee designated by a
majority of the holders of
-3-
4
Series C Preferred Stock is ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, (v) the initial nominee designated
by the directors pursuant to clause (v) of Section 4(b) is ▇▇▇▇▇▇ ▇▇▇▇▇▇, (vi)
the initial nominee designated by the directors elected pursuant to clauses (ii)
through (v) of Section 4(b) above is ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ and (vii) the initial
nominees elected pursuant to clause (vii) of Section 4 (b) are ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
and ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇.
(e) The Board of Directors shall be expanded by up to one
additional member if it is deemed desirable by a majority of the Series A-1
Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D
Preferred Stock, Series E Convertible Preferred Stock, $.01 par value per share
(the "Series E Preferred Stock"), Series A-2 Preferred Stock, Series B-2
Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock and
Series E-2 Convertible Preferred Stock, $.01 par value per share (the "Series
E-2 Preferred Stock" and together with the Series A-1 Preferred Stock, Series
B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series
E Preferred Stock, Series A-2 Preferred Stock, Series B-2 Preferred Stock,
Series C-2 Preferred Stock and Series D-2 Preferred Stock, the "Preferred
Stock") voting together. The nominees to fill the directorship(s) created by the
expansion of the Board of Directors shall be designated by a majority of the
directors elected pursuant to clauses (ii) through (v) of Section 4(b) above,
provided, however, that the nominee(s) designated pursuant to this paragraph (e)
shall not be any person affiliated with the Company's management or the holders
of Preferred Stock. The Board of Directors will be enlarged and the designated
nominees will be elected in accordance with the Company's By-laws.
5. Vacancies. Subject to paragraph (c) of Section 4 above, any vacancy
in the Board of Directors of the Company (occurring due to the resignation,
death or removal of a director or due to the expansion of the Board of Directors
pursuant to paragraph (e) above) shall be filled by a nominee elected by the
parties who had the right to elect the nominee for such vacant directorship
pursuant to Section 4 (b) above or pursuant to paragraph (e) above, as
applicable.
6. Miscellaneous.
(a) This Agreement sets forth the entire agreement of the
parties with respect to the subject matter hereof and may not be amended,
modified or terminated, and no rights or provisions herein may be waived,
without the written consent of (i) the holders of at least 55% of the then
outstanding shares of Preferred Stock, voting together as a single class, and
(ii) the holders of a majority of the outstanding shares of Common Stock of the
Company held by those who are or have become a party to this Agreement, provided
that the provisions of Section 3(i) of this Agreement may not be waived without
the written consent of holders of at least 80% of the then outstanding shares of
Preferred Stock, voting separately as a single class.
-4-
5
(b) This Agreement shall be governed by and construed and
enforced in accordance with the laws of the Commonwealth of Massachusetts. This
Agreement shall be binding upon and inure to the benefit of the parties
signatory hereto and their respective heirs, personal representatives,
successors or assigns and any transferee of any of the Shares. Notwithstanding
anything to the contrary in this Agreement, the Company acknowledges and agrees
that Artal Luxembourg S.A. may transfer the shares of Series E Preferred Stock
and Warrants acquired by it under the Purchase Agreement to QuestMark Partners,
L.P. and/or any of its affiliates ("QuestMark") without restriction (other than
compliance with applicable securities laws), and that subsequent to such
transfer, QuestMark shall be deemed a Preferred Shareholder for all purposes
under this Agreement. At the time of the transfer, QuestMark shall deliver to
the Company a written instrument by which it agrees to be bound by the
obligations imposed under this Agreement, to the same extent as if it were a
Preferred Shareholder hereunder.
(c) The parties acknowledge and agree that in the event of any
breach of this Agreement, remedies at law will be inadequate, and each of the
parties hereto shall be entitled to specific performance of the obligations of
the other parties hereto and to such appropriate injunctive relief as may be
granted by a court of competent jurisdiction.
(d) This Agreement may be executed in a number of
counterparts, all of which together shall for all purposes constitute one
Agreement, binding on all the parties hereto, notwithstanding that all such
parties have not signed the same counterpart.
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
-5-
6
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date and year first above written.
ASPECT MEDICAL SYSTEMS, INC.
By:/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
----------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
President
ARTAL LUXEMBOURG S.A.
By:/s/▇▇▇▇ ▇. Komler
----------------------------------------
Name: ▇▇▇▇ ▇. Komler
Title: Managing Director
BENEFIT CAPITAL MANAGEMENT
CORPORATION, as Investment Manager of
the Prudential Insurance Company of America
Separate Account #VCA-GA-5298
By:/s/▇▇▇ ▇▇▇▇▇▇▇
----------------------------------------
Name: ▇▇▇ ▇▇▇▇▇▇▇
Title: Sr. VP & CFO
HLB/CB Fund, L.P.
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇.
----------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇.
Title: General Partner
▇▇▇▇▇ CAPITAL PARTNERS
By:/s/J. ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇.
----------------------------------------
Name:
Title:
US DEVELOPMENT CAPITAL INVESTMENT
COMPANY
By:/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇
----------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
Title: Corporate Secretary
[Fourth Amended and Restated Voting Agreement]
7
NEW VENTURE PARTNERS III, LIMITED
PARTNERSHIP
By: /s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
----------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
Title: General Partner
CITIVENTURE 96 PARTNERSHIP, L.P.
By: Chancellor LGT Asset Management, Inc.
as investment advisor
By:/s/▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
----------------------------------------
Name:
Title:
JULIET CHALLENGER, INC.
By:/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
----------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Title: Vice President
ORCHID & CO., nominee for
▇. ▇▇▇▇ Price Threshold Fund III, L.P.
By:▇. ▇▇▇▇ Price Threshold Fund Associates, Inc.
General Partner
By:/s/▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
----------------------------------------
Name: ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Title: Vice President
LANDMARK VENTURE CAPITAL
PARTNERS, LIMITED PARTNERSHIP
By:/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
----------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
Title: General Partner
/s/▇▇▇▇▇ ▇▇▇▇▇
------------------------------------------
▇▇▇▇▇ ▇▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
8
/s/▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ and
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇, Trustees of the ▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇ Trust U/A dated 11/18/85
VENHILL LIMITED PARTNERSHIP
By:/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
Name:
Title: General Partner
CHANCELLOR LGT PRIVATE CAPITAL
PARTNERS III, L.P.
By: CPCP Associates, L.P., its general partner
By: Chancellor LGT Venture Partners, Inc.,
its general partner
By:/s/▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
------------------------------------------
Name:
Title:
/s/▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
HIGHLAND CAPITAL PARTNERS II,
LIMITED PARTNERSHIP
By: Highland Management Partners II
Limited Partnership, its General
Partner
By:/s/▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Title: GP
[Fourth Amended and Restated Voting Agreement]
9
▇▇▇▇▇▇▇ RIVER PARTNERSHIP VII,
LIMITED PARTNERSHIP
By:/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
------------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
Title: General Partner
POLARIS VENTURE PARTNERS, L.P.
By: Polaris Venture Management Co., LLC
Its General Partner
By:/s/▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------------------
Member
/s/▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ /s/▇. ▇. ▇▇▇▇▇▇
------------------------------------------
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
Trustees U/A/T dated 8/28/68 for ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
/s/▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ /s/▇. ▇. ▇▇▇▇▇▇
------------------------------------------
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
Trustees U/A/T dated 8/28/68 for ▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇, ▇▇.
/s/▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ /s/▇. ▇. ▇▇▇▇▇▇
------------------------------------------
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
Trustees U/A/T dated 8/28/68 for Juliet ▇▇▇
▇▇▇▇▇▇▇
/s/▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ /s/▇.▇. ▇▇▇▇▇▇
------------------------------------------
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
Trustees U/A/T dated 8/28/68 for ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
/s/▇▇▇▇ ▇▇ ▇▇▇▇▇▇
------------------------------------------
▇▇▇▇ ▇▇ ▇▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
10
/s/▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
ONE LIBERTY FUND III, L.P.
By: One Liberty Partners III, L.P.,
Its General Partner
By: /s/▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
General Partner
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇▇
GENSTAR INVESTMENT CORPORATION
By:/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Executive Vice President
/s/▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇ and/or ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇
Trustees or Successor Trustees under The
▇▇▇▇▇ Trust U/A/D 10/05/88
[Fourth Amended and Restated Voting Agreement]
11
POLARIS VENTURE PARTNERS
FOUNDERS' FUND, L.P.
By: Polaris Venture Management Co., LLC
Its General Partner
By:/s/▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------------------
Member
/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
ABS EMPLOYEE VENTURE FUND LIMITED
PARTNERSHIP
By:/s/▇▇▇▇▇▇▇▇-▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇▇▇▇-▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Title: VP of ▇▇▇▇ ▇▇▇▇▇ Investments,
GP of the Partnership
SECOND CENTURY GROWTH DEFERRED
COMPENSATION PLAN: ▇▇▇▇▇ ▇▇▇▇▇▇▇, Inc.
By:/s/▇▇▇▇▇ ▇▇▇▇▇▇▇, Inc.
------------------------------------------
Name: Buzz ▇▇▇▇▇▇
Title:
THE ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ SCHOOL
ENDOWMENT FUND
By:/s/▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------------------
Name:
Title:
/s/▇▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
12
GILDE INTERNATIONAL B.V.
By: One Liberty Partners III, L.P.,
its Attorney-in-Fact
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
---------------------------------------
Title: General Partner
▇▇▇▇▇▇▇▇ Associates Fund, ▇▇▇▇▇▇▇▇ ASSOCIATES FUND
A California Limited Partnership
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
---------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Authorized Signatory
▇▇▇▇▇▇▇▇ Medical Partners, ▇▇▇▇▇▇▇▇ MEDICAL PARTNERS
A California Limited Partnership
By: ▇▇▇▇▇▇▇▇ VI Investment Partners
By: ▇▇▇▇▇▇▇▇ VI Investment
Partners, A California By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Limited Partnership, Its ---------------------------------------
General Partner Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Authorized Signatory
By: ▇▇▇▇▇▇▇▇ VI Management
Partners, A California ▇▇▇▇▇▇▇▇ VI INVESTMENT PARTNERS
Limited Partnership,
General Partner of By: ▇▇▇▇▇▇▇▇ VI Management Partners
▇▇▇▇▇▇▇▇ VI Investment
Partners By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
--------------------------------------
▇▇▇▇▇▇▇▇ VI Investment Partners, Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
A California Limited Partnership Title: Authorized Signatory
By: ▇▇▇▇▇▇▇▇ VI Management MERRILL, PICKARD, ▇▇▇▇▇▇▇▇ &
Partners, A California EYRE IV, LIMITED PARTNERSHIP
Limited Partnership, Its
General Partner By: MPAE IV Management Co., L.P.
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Title: General Partner
[Fourth Amended and Restated Voting Agreement]
13
NEW ENTERPRISE ASSOCIATES IV,
LIMITED PARTNERSHIP
By: New Enterprise Associates IV, Limited
Partnership
By: NEA Partners IV, Limited
Partnership
By: /s/▇▇▇▇▇ ▇▇▇▇▇▇
----------------------------
▇▇▇▇▇ ▇▇▇▇▇▇
General Partner
HLM PARTNERS VII, L.P.
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇.
------------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇.
Title: General Partner
▇▇▇▇▇▇ ▇▇▇▇ VENTURES, A CALIFORNIA
LIMITED PARTNERSHIP
By:/s/G. ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇.
------------------------------------------
Name: G. ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇.
Title: Managing Director of the General
Partner
TOW PARTNERS, A CALIFORNIA LIMITED
PARTNERSHIP
By:/s/▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: General Partner
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇., Trustee of the
Younger Living Trust
/s/▇▇▇▇ ▇. ▇▇▇▇▇▇
--------------------------------------------
▇▇▇▇ ▇. and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Trustees of
the Wythes Living Trust
[Fourth Amended and Restated Voting Agreement]
14
/s/G. ▇▇▇▇▇▇▇ ▇▇▇▇▇
------------------------------------------
G. ▇▇▇▇▇▇▇ ▇▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Under Power of Attorney
------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Under Power of Attorney
------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
/s/▇▇▇▇▇ ▇▇▇▇
------------------------------------------
▇▇▇▇▇ ▇▇▇▇
/s/▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇▇ and ▇▇▇▇ ▇▇▇▇▇▇▇
H&D INVESTMENTS II
By: /s/▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Partner
/s/▇. ▇▇▇▇▇▇▇▇▇▇▇▇ Eagle
------------------------------------------
▇. ▇▇▇▇▇▇▇▇▇▇▇▇ Eagle
--------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇
/s/J. ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
------------------------------------------
J. ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
15
THE ▇▇▇▇ CARDIOVASCULAR
RESEARCH FOUNDATION
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Treasurer
/s/▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇▇
ZED INTERNATIONAL, INC.
By:
------------------------------------------
BAYVIEW INVESTORS, LTD.
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇
Title: Authorized Signatory
INTERSTOCK ANSTALT
By:/s/Ernst Bloathlinger
------------------------------------------
Authorized Signatory
SVE STAR VENTURE ENTERPRISES NO. V,
A GERMAN CIVIL LAW PARTNERSHIP
(WITH LIMITATION OF LIABILITY)
By: SVM Star Ventures Management
gesellschaft mbH Nr. 3
By: /s/▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
------------------------------------------
Authorized Signatory
[Fourth Amended and Restated Voting Agreement]
16
SVM STAR VENTURES
MANAGEMENTGESELLSCHAFT MBH NR.
3 & CO. BETEILIGUNGS KG
By: SVM Star Ventures Management
gesellschaft mbH Nr. 3
By: /s/▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------
Authorized Signatory
/s/▇▇▇▇▇▇▇ ▇▇▇▇▇▇ /s/▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------------------
▇▇▇▇▇▇▇ and ▇▇▇▇▇ ▇▇▇▇▇▇
AENEAS VENTURE CORPORATION
By:/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------------
Authorized Signatory
CATALYST VENTURES, LIMITED
PARTNERSHIP
By: New Enterprise Associates IV, Limited
Partnership
By: NEA Partners IV, Limited
Partnership
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------
Name:
Title:
▇▇▇▇▇ FARGO BANK, TRUSTEE SHV
M/P/T FBO ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇ /s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Trust Officer
[Fourth Amended and Restated Voting Agreement]
17
▇▇▇▇▇ FARGO BANK, TRUSTEE SHV
M/P/T FBO ▇▇▇▇▇ ▇▇▇▇
By:/s/▇▇▇▇▇ ▇. ▇▇▇▇▇▇ /s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Trust Officer
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
THE ▇▇▇▇▇▇▇ RESEARCH FOUNDATION
By:/s/▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------------------
Name:
Title:
FISHERS ISLAND PARTNERS
By: /s/▇▇▇▇▇▇ Saint-▇▇▇▇▇, MD
------------------------------------------
Name:
Title: Managing Partner of
▇▇▇▇▇▇ Island Partners
/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------------
Ziad and ▇▇▇▇ ▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇ ▇▇▇▇▇▇ as Custodian for ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇ as Custodian for ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇, M.D.
--------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
/s/▇▇▇▇ ▇▇▇ Young
--------------------------------------------
▇▇▇▇ ▇▇▇ ▇▇▇▇▇
/s/▇▇▇▇▇▇ ▇▇▇▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
18
--------------------------------------------
▇▇▇▇ ▇. Rohrbasser
--------------------------------------------
▇▇▇▇▇▇▇▇ ▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
/s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇
/s/▇▇▇▇▇▇ ▇. ▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇
/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇
--------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇
NEW VENTURE PARTNERS IV, LIMITED
PARTNERSHIP
By:/s/▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
--------------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
Title: Gerneral Partner
[Fourth Amended and Restated Voting Agreement]
19
SCHEDULE I
PREFERRED SHAREHOLDERS
Artal Luxembourg S.A.
Attn: ▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇, ▇▇▇▇▇-▇▇▇
▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
Benefit Capital Management Corporation
as Investment Manager for the Prudential
Insurance Company of America
Separate Account Number VCA-GA-5298
c/o ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
HLB/CB Fund, L.P.
HLM Management Company
c/o ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, #▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ Capital Partners, a division of
▇▇▇▇▇ National Corporation
c/o J. ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇.
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇ Development Capital Investment
Company
▇/▇ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇▇, ▇▇▇▇, ▇▇▇▇▇, and ▇▇▇▇▇, LLP
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
and ▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇, Trustees of the
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Trust U/A dated
11/18/85
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
Trustees U/A/T dated 8/28/68 for Juliet Trustees U/A/T dated 8/28/68 for
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
Trustees U/A/T dated 8/28/68 for Trustees U/A/T dated 8/28/68 for
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
1800 ▇▇▇▇▇ Building ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Venhill Limited Partnership Juliet Challenger, Inc.
c/o ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
Autotrol Technology ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Attn: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
with copy to:
▇▇▇▇▇ ▇▇▇▇▇
Taconic Group, Inc.
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
ABS Employees' Venture Fund Limited Second Century Growth Deferred
Partnership Compensation Plan: ▇▇▇▇▇ ▇▇▇▇▇▇▇, Inc.
c/o ▇▇▇ ▇▇▇▇▇▇ c/o Buzz ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇. ▇▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇., ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
21
The ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ School Endowment ▇▇▇▇▇▇ Afeyen
Fund c/o PerSeptive Biosystems
c/o ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇. ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
c/o Exact Laboratories, Inc. ▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Polaris Venture Partners, L.P. Landmark Ventures, Limited Partnership
Bay Colony Corporate Center ▇▇▇▇ ▇▇. ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Polaris Venture Partners Founders' Fund, Aeneas Venture Corporation
L.P. ▇/▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Center Company, Inc.
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
One Liberty Fund III, L.P. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
One Liberty Square c/o Sutter ▇▇▇▇ Ventures
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Gilde International B.V. Genstar Investment Corporation
▇/▇ ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
Partners III, L.P. ▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
One Liberty Square Attn: ▇▇. ▇. ▇. ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
22
▇▇▇▇▇▇▇ River Partnership VII, ▇▇▇▇▇ Fargo Bank, Trustee
Limited Partnership SHV M/P/T FBO ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Ten Post Office Square, Attn: ▇▇▇▇▇ ▇▇▇▇▇▇
Suite 1330 MAC #0101-021
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
New Enterprise Associates IV, ▇▇▇▇▇ Fargo Bank, Trustee
Limited Partnership SHV M/P/T FBO ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇ ▇▇. ▇▇▇▇ ▇▇▇▇▇▇ Attn: ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ MAC #0101-021
▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
New Venture Partners III, Limited Catalyst Ventures, Limited
Partnership Partnership
▇▇▇▇ ▇▇. ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇. ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Highland Capital Partners II, The ▇▇▇▇▇▇▇ Research Foundation
Limited Partnership ▇▇. ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
One International Place Professor of Anesthesia
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ University of Utah
Medical School
Department of Anesthesia
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇ Associates ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ W. ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇ Medical Partners Ziad and ▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
23
▇▇▇▇▇▇▇▇ VI ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ Ventures, ▇▇▇▇ ▇▇ ▇▇▇▇▇▇
a California Limited Upstar Consulting
Partnership ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇
▇/▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Tow Partners, a California ▇▇▇▇▇▇ ▇▇▇▇▇▇ as Custodian for
Limited Partnership ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇/▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Suite A 200
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇. and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, M.D.
Trustees of the Wythes Living Trust ▇ ▇▇▇▇▇ ▇▇▇▇▇▇
c/o Sutter ▇▇▇▇ Ventures ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
G. ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇
c/o Sutter ▇▇▇▇ Ventures ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Suite A 200
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇., ▇▇▇▇ ▇▇▇ ▇▇▇▇▇
Trustee of the Younger Living Trust ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇/▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
24
▇▇▇▇▇ ▇▇▇▇ Zed International, Inc.
c/▇ ▇▇▇▇▇▇ Hill Ventures c/o ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
755 Page Mill Road BankBoston, N.A.
Suite A 200 01-05-03
Palo ▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇.▇. ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ &
c/▇ ▇▇▇▇▇▇ ▇▇▇▇ Ventures ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇ ▇ ▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ The ▇▇▇▇ Cardiovascular Fdn.
c/o Sutter ▇▇▇▇ Ventures ▇▇▇▇▇▇ ▇▇▇▇, Treasurer
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇ ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇. ▇▇▇▇
▇/▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇ ▇▇▇ ▇▇▇▇▇▇'▇ ▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Suite A 200
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Genstar Investment Corporation J. ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇ # ▇▇▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
Merrill, Pickard, ▇▇▇▇▇▇▇▇ & ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ Eagle
Eyre IV Limited Partnership Box 1197
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Suite 1080
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
25
H&D Investments II ▇▇▇▇ ▇▇▇▇▇▇, MD
▇/▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, MD
▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, M.D. Interstock Anstalt fur Vermogens und
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇/▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇ ▇▇
FL-9490 Vaduz
Liechtenstein
▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇▇▇▇ & ▇▇▇▇▇ ▇▇▇▇▇▇
7 Fanueil Halll ▇ ▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Bayview Investors, Limited
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ & ▇▇.
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
80 Rollingwood Land ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇ ▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
HLM Partners VII, L.P. Orchid & Co., nominee for
HLM Management ▇. ▇▇▇▇ Price Threshold
c/o ▇▇▇▇▇ ▇▇▇▇ Fund III, L.P.
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, #▇▇▇▇ ▇/▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇. ▇▇▇▇ Price Assoc. Inc.
▇▇▇ ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
26
SVE Star Venture Enterprises ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
No. V A German Civil Law c/o Aspect Medical Systems, Inc.
Partnership (with limitation of 2 Vision Drive
liability) ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
c/o ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Star Venture Managment
▇▇▇▇▇▇▇▇▇▇. ▇
▇-▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇
SVM StarVentures Chancellor LGT Private Capital Partners
Managementgesellschaft mbH Nr.3 III, L.P.
& Co. Beteilungs KG c/o ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
c/o ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ 1166 Avenue of the Americas
Star Venture Managment ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇. ▇
▇-▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇
Citiventure 96 Partnership, L.P. Fishers Island Partners
c/o ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ c/o ▇▇▇▇▇▇ Saint-▇▇▇▇▇, M.D.
1166 Avenue of the Americas ▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, M.D. ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇
▇/▇ ▇▇▇▇. ▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇-▇▇▇▇▇ c/o ▇. ▇. ▇▇▇▇ & Co.
Stanford University Hospital ▇ ▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Nina Rohrbasser ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
c/o ▇. ▇. ▇▇▇▇ & Co. ▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
[Fourth Amended and Restated Voting Agreement]
27
Schedule II
ASPECT MEDICAL SYSTEMS, INC.
INSTRUMENT OF ACCESSION
The undersigned, ______________________, as a condition precedent to
becoming the owner or holder of record of _________________ ( ) shares of the
capital stock, of Aspect Medical Systems, Inc., a Delaware corporation (the
"Corporation"), hereby agrees to become a party to and bound by that certain
Fourth Amended and Restated Voting Agreement, dated as of December __, 1998, by
and among the Corporation and other shareholders of the Corporation. This
Instrument of Accession shall take effect and shall become an integral part of
the said Third Amended and Restated Voting Agreement immediately upon execution
and delivery to the Corporation of this Instrument.
IN WITNESS WHEREOF, this INSTRUMENT OF ACCESSION has been duly executed
by or on behalf of the undersigned, as a sealed instrument under the laws of the
Commonwealth of Massachusetts, as of the date below written.
Signature: __________________________
Print Name:___________________________
Date: _______________________
Address:_______________________________
_______________________________________
_______________________________________
Accepted by:
ASPECT MEDICAL SYSTEMS, INC.
By: ___________________________
Date: __________________________
[Fourth Amended and Restated Voting Agreement]
